Evaluation of the efficacy of simplified nutritional instructions from physicians on dietary salt restriction for patients with type 2 diabetes mellitus consuming excessive salt: protocol for a randomized controlled trial

Emi Ushigome, Chikako Oyabu, Makoto Shiraishi, Nobuko Kitagawa, Aya Kitae, Keiko Iwai, Hidetaka Ushigome, Isao Yokota, Masahide Hamaguchi, Masahiro Yamazaki and Michiaki Fukui

Abstract

Background: Hypertension is present in more than 50% of patients with type 2 diabetes mellitus. Dietary salt restriction is recommended for the management of high blood pressure. Instructions on dietary salt restriction, provided by a dietitian, have been shown to help patients reduce their salt intake. However, appointments for the dietitians in hospitals are often already fully booked, making it difficult for patients to receive instructions on the same day as the outpatient clinic visit.

Aim: The aim of this trial is to test a new intervention to assess whether guidance on dietary salt restriction provided by physicians during outpatient visits is effective in reducing salt intake in patients with type 2 diabetes mellitus who have an excessive salt intake.

Methods: In this unblinded randomized controlled trial (RCT), a total of 200 patients, male or female, aged between 20 and 90 years, who have type 2 diabetes mellitus and consume excessive salt will be randomly assigned to two groups: an intervention group and a control group. In addition to being given routine treatment, participants in the intervention group will be given individual guidance on restricting their dietary salt intake by a physician upon enrollment. The control group will only be given routine treatment. Participants will be followed up for 24 weeks. The primary outcome will be dietary salt intake, which will be assessed at baseline and at 8, 16, and 24 weeks. The secondary outcomes, including body weight, body mass index, hemoglobin A1c level, blood pressure, blood glucose level, serum lipid profile, and urinary albumin excretion level, will be assessed at baseline and at 8, 16, and 24 weeks.

(Continued on next page)
Discussion: The results of this RCT have the potential to provide a simple and novel clinical approach to reduce salt intake among patients with type 2 diabetes, making regular visits to their physician, in outpatient facilities. This protocol will contribute to the literature because it describes a practical intervention that has not been tested previously, and it may serve as guidance to other researchers interested in testing similar interventions.

Trial registration: University Hospital Medical Information Network (UMIN), UMIN000028809. Registered retrospectively on 24 August 2017. http://www.umin.ac.jp.

Keywords: Daily salt intake, Dietary salt restriction, Simplified nutritional instructions, Randomized controlled trial, Sodium, Type 2 diabetes mellitus

Introduction
According to a recent estimate, about 425 million adults around the world and an estimated 158.8 million adults in the Western Pacific Region are living with diabetes mellitus (DM) [1]. Among the International Diabetes Federation regions, the Western Pacific Region has the highest number of adults living with DM [1, 2]. Moreover, the prevalence of both type 1 and type 2 DM (T2DM) has increased significantly during recent decades [3]. T2DM, being much more common, has been the main driver for the increase in global diabetes prevalence [3]. The results of the National Health and Nutrition Survey in Japan, released in September 2017, reported that there were an estimated 20 million patients with T2DM and prediabetes, of which 10 million patients had T2DM [4].

Hypertension is present in more than 50% of patients with T2DM and contributes significantly to microvascular and macrovascular diseases in T2DM [5]. Moreover, the incidence of cardiovascular disease markedly increases when the two diseases coexist [6]. Thus, intensive treatment of high blood pressure, in addition to hyperglycemia, is important for patients with T2DM.

Epidemiological studies have shown that excessive salt intake is directly related to cardiovascular mortality and to an increase in blood pressure [7]. Many hypertension guidelines recommend salt restriction, based on studies that have demonstrated a decrease in blood pressure with a reduction in salt intake [8, 9]. We have previously reported in a single-arm trial that nutritional instructions on dietary salt restriction by a national registered dietitian provided to patients with T2DM consuming excessive salt may be beneficial in reducing dietary salt intake and home blood pressure [10]. In that study, daily salt intake was significantly reduced by 0.8 g at 2 months and 0.7 g at 6 months after the instruction. Moreover, morning systolic blood pressure was significantly reduced by 2.7 mmHg at 2 months and 5.8 mmHg at 6 months after the instruction. However, dietitians are usually too busy to see patients during their regular clinic visits. Therefore, it would have great clinical significance if this study can demonstrate that shorter and more focused nutritional instructions given to patients by their regular physicians during regular outpatient visits are effective. It might contribute to reducing the financial burden on patients and also the need for patients to have separate consultations with a dietitian.

We plan to investigate a new method of providing advice to patients with T2DM regarding dietary salt restriction for the management of hypertension: nutritional instructions will be given to patients by their regular physicians during regular outpatient visits.

Aims of study
This randomized controlled trial (RCT) will evaluate whether simplified instructions on how to reduce salt intake, provided by a physician using standardized nutritional guidance materials, will help patients with T2DM consuming excessive salt to reduce their salt intake.

Methods
Study design
The study will be an unblinded RCT aimed at testing whether instructions on dietary salt restriction provided by physicians during outpatient visits is effective in reducing salt intake in patients with type T2DM who have an excessive salt intake. A total of 200 patients with T2DM and excessive salt intake (150 from the Hospital of the Kyoto Prefectural University of Medicine, 50 from Kyoto First Red Cross Hospital according to the proportion of outpatients) will be randomly assigned to an intervention group or a control group, using permuted block randomization, with block sizes of ten. Spot morning urine tests will be performed, and the results will be used to estimate their salt intake. The primary outcome will be the change in daily salt intake between baseline and 24 weeks. Each participant will be enrolled for 24 weeks from randomization to the final follow-up assessment and will visit every 8 weeks (Fig. 1).

The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist is provided as Additional file 1.

Study setting
The study will be conducted in outpatient clinics at the Hospital of the Kyoto Prefectural University of Medicine.
and Kyoto First Red Cross Hospital. Participants will be recruited in the outpatient clinics, and all study visits will be conducted in outpatient clinics.

**Recruitment**
Participants will be recruited from April 2016 to December 2020.

**Inclusion criteria**
Patients will be considered for inclusion in the study if they meet all of the following inclusion criteria: willing and able to give informed consent for participation in this study; male or female, aged between 20 and 90 years old; diagnosed with T2DM (we will apply the Japan Diabetes Society’s “Committee report on classification and diagnostic criteria of diabetes mellitus” for diagnosing diabetes [11]); and salt intake ≥ 6 g per day in patients with hypertension [12], salt intake ≥ 7 g per day in female patients without hypertension, or salt intake ≥ 8 g per day in male patients without hypertension [13]. Daily salt intake will be measured using a spot morning urine sample.

**Exclusion criteria**
Patients will be excluded from the study if they have any of the following exclusion criteria: history of or features indicative of an eating disorder; secondary hypertension or malignant hypertension; pregnant, breast-feeding, or planning to become pregnant within the next 6 months; myocardial infarction, cerebrovascular accident, or hospitalization for angina pectoris within the previous 6 months; change in antihypertensive medication and/or antidiabetic medication within the previous month; cardiac failure (grade II, III, or IV according to the New York Heart Association) [14]; atrial fibrillation or severe arrhythmia; advanced renal failure (serum creatinine greater than or equal to 2.0 mg/dL or patient currently on dialysis); life-threatening condition such as a malignant tumor; intercurrent serious infection; significant psychiatric disorder or diagnosed substance abuse; serious neurological disorder, including epilepsy; unable to change their diet (currently in a facility or using home delivery); or recruiting physician considers the patient to be unsuitable for the study for any other reason.

**Study procedures**
After confirming that a patient is eligible for the study, written informed consent will be obtained. Upon enrollment, the participants will be randomized to the intervention group or the control group.

**Control group**
During their baseline visit, participants allocated to the control group will be informed of their current salt intake but will not be given instructions by their physician on how to reduce their salt intake. Their physician will give them the same dietary guidance that is routinely given to patients during outpatient visits.

**Intervention group**
During the baseline visit, participants allocated to the intervention group will be informed of their current salt intake and will be given instructions by their physician on how to reduce their salt intake. This will take about 10 min. (For further details, see the Intervention section.) The intervention group will also receive routine education along with educational intervention.

All participants will be asked to attend follow-up visits 8, 16, and 24 weeks after enrollment.

**Allocation**
All participants will be randomized to one of the two arms (intervention or control) in equal ratios, using permuted block randomization, with block sizes of ten. An independent researcher will draw lots to assign each participant to a group directly after obtaining the participant’s informed consent. Because of the nature of this study, it will not be possible to blind participants, physicians, or some of the researchers to the treatment allocation.
**Intervention**

During the baseline visit, participants in the intervention group will be informed of their current daily salt intake and the salt intake recommendation levels (as noted in the inclusion criteria) by their regular physician, who will then give them instructions on how to reduce their salt intake, including clear recommendations for food swaps (e.g., change soy sauce to low salt soy sauce). The materials (pamphlets) used and the doctors’ instructions will be standardized. Instructions on reducing salt intake will be given using pamphlets describing “Twelve tips on reducing salt intake” (listed below); “Specific examples of amount of seasoning equivalent to 1 g of salt”; and “Concrete example of estimated amount of salt contained in food (menu for eating out, dried fish, paste products, processed food, instant food, pickles, *tsukudani*, and delicacies)”. The intervention will take about 10 min. Participants will also be informed of their current daily salt intake at the 8-week and 16-week study visits.

The 12 tips on reducing salt intake are:

1. Get used to more mild flavors.
2. Limit your intake of pickles and soup.
3. Use salt sparingly.
4. Dip, do not douse, food in salty sauces such as soy sauce.
5. Flavor food with sour-tasting ingredients.
6. Use spices liberally.
7. Use natural aromatic seasonings such as herbs and perilla.
8. Fragrant smells are your friend (grill, roast, toast, etc.).
9. Use flavorful oils such as sesame oil, olive oil, and herbal oil.
10. Limit your intake of snacks that you eat with alcohol.
11. Limit your intake of fish cakes and processed foods.
12. Do not overeat.

**Measurements and outcomes**

All outcome measures will be assessed at baseline and at the 2-month, 4-month, and 6-month follow-up visits.
Betic Neuropathy Study Group [16]. Criteria for diabetic polyneuropathy proposed by the Diabetes Control and Complications Trial is as follows: 

- Presence of diabetic neuropathy will be assessed from chart reviews.

- The presence of nephropathy will be assessed by dividing the UAE into three categories, as follows: normoalbuminuria, UAE < 30 mg/g Cr; microalbuminuria, 30–300 mg/g Cr; or macroalbuminuria, > 300 mg/g Cr.

- Neuropathy will be defined based on the diagnostic criteria for diabetic polyneuropathy proposed by the Diabetic Neuropathy Study Group [16].

- Macrovascular complications will be defined as the presence of previous cardiovascular disease, cerebrovascular disease, or arteriosclerosis obliterans, on the basis of clinical history or physical examination.

- Changes in diabetic medication (number of drugs currently prescribed to the patient; dose of drugs; initiation of new medication during study period; initiation of injectable diabetic medication; initiation of insulin; number of medications stopped or changed during the study period) and changes in antihypertensive medication (number of drugs started and stopped during study period; dose of drugs; initiation of new medication during study period) will be recorded. We will exclude patients from the analysis who were newly prescribed or stopped thiazide diuretics and sodium glucose transporter 2 inhibitors during the study.

**Primary outcome**

The primary outcome will be dietary salt intake and will be assessed at baseline and at 8, 16, and 24 weeks. For feasibility, daily salt intake will be measured using a spot morning urine sample and will be calculated using the following equation:

\[
\text{Daily salt intake (g/day)} = 0.0585 \times 21.98 \times \left(\frac{\text{urinary sodium (mEq/L)/urinary creatinine (mg/dL)}}{14.89 \times \text{body weight (kg) + 16.14 \times height (cm) - 2.04 \times age (years) - 2244.45}}\right)^{0.392} [15].
\]

Spot morning urine samples will be collected using an immunoturbidimetric assay (Autokit Micro Albumin, Wako, Osaka, Japan).

**Secondary outcomes**

The secondary outcomes will include body weight, hemoglobin A1c, blood pressure, serum lipid profile (triglycerides and high-density lipoprotein cholesterol), estimated glomerular filtration rate, and urinary albumin excretion (UAE) [9]. Blood samples for biochemical measurements will be taken in the morning.

- Hemoglobin A1c level, serum lipid profile, and other biochemical data will be determined using standard laboratory measurements. The UAE will be measured with an immunoturbidimetric assay. The hemoglobin A1c level will be expressed in National Glycohemoglobin Standardization Program units. Information on age, duration of diabetes, smoking status, alcohol consumption, and use of medication will be collected from each participant at baseline.

- The presence of retinopathy will be assessed from chart reviews.

- The presence of nephropathy will be assessed by dividing the UAE into three categories, as follows: normoalbuminuria, UAE < 30 mg/g Cr; microalbuminuria, 30–300 mg/g Cr; or macroalbuminuria, > 300 mg/g Cr.

- Neurpathy will be defined based on the diagnostic criteria for diabetic polyneuropathy proposed by the Diabetic Neuropathy Study Group [16].

- Macrovascular complications will be defined as the presence of previous cardiovascular disease, cerebrovascular disease, or arteriosclerosis obliterans, on the basis of clinical history or physical examination.

- Changes in diabetic medication (number of drugs currently prescribed to the patient; dose of drugs; initiation of new medication during study period; initiation of injectable diabetic medication; initiation of insulin; number of medications stopped or changed during the study period) and changes in antihypertensive medication (number of drugs started and stopped during study period; dose of drugs; initiation of new medication during study period) will be recorded. We will exclude patients from the analysis who were newly prescribed or stopped thiazide diuretics and sodium glucose transporter 2 inhibitors during the study.

**Statistical methods**

A mixed model will be used to analyze the factors involved in sodium intake. Factors and changes in factors that may influence sodium intake will be adjusted in multivariate models. Subgroup analyses will be conducted stratified by age (< 65 years or ≥ 65 years), sex (male or female), body mass index (< 22%, or ≥ 22%), and hemoglobin A1c levels (< 7%, or ≥ 7%) to investigate the coherency of educational effect among subgroups.

The secondary outcomes will be compared using separate regression models. The differences of values between the two groups with 95% confidence interval and a p value < 0.05 will also be presented. We will use an intention-to-treat analysis. JMP version 11.2.0 software (SAS Institute, Cary, NC, USA) will be used as the statistical software package for the analysis. All analyses will be two-sided, and p values < 0.05 will be considered statistically significant. Multiple imputations will be applied if there are missing values. In a previous study, it was shown that after patients with T2DM were given instructions on reducing salt intake, their salt intake declined from 10.3 ± 1.6 g to 9.3 ± 1.9 g per day [10]. Therefore, we have based our sample size calculation on the assumption that the intervention group will show a 1-g reduction in their daily salt intake, and that the salt intake in the control group will remain unchanged. With the two-sided significance level set at 5.0% and power set at 80%, the required sample size will be 90 participants in each group. Assuming a 10% dropout rate [17], a total of 200 participants will be required for both groups combined.

**Patient and public involvement**

Patients are not consulted about how to design a medical protocol, research questions, or outcome measures for an intervention relating to health outcomes. Patients are given a description of the study with their consent forms. They are also provided with results at the conclusion of the study. Control participants are offered the opportunity to be given the protocol at the completion of the study, pending positive outcomes.

**Discussion**

Observational studies have indicated that most people consume an excess level of salt and that excessive salt intake may contribute to hypertension, which is a risk factor for various diseases, such as stroke, coronary heart disease, and nephropathy [7]. Therefore, salt restriction is essential for the prevention of cardiovascular disease and is recommended in many guidelines. This study is a
randomized controlled trial on the effect of providing patients with simplified instructions on how to reduce salt intake from their regular physician during a regular clinic visit, using standard nutritional guidance materials. Demonstrating that shorter and more focused instructions during regular outpatient visits are effective would have great clinical significance. This protocol will contribute to the literature because it describes a practical intervention that has not been tested previously, and it may serve as guidance to other researchers interested in testing similar interventions.

Results will be reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines and will be disseminated via peer-reviewed publications and presentations at national and international conferences.

**Trial status**

The trial is ongoing. The protocol version number is R000026346. Recruitment began on April 1, 2016. The approximate date when recruitment will be completed is March 31, 2020.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s13063-019-3864-8.

**Acknowledgements**

We would like to thank Editage (www.editage.com) for the English language editing.

**Dissemination policy**

Results will be reported in accordance with the CONSORT guidelines and will be disseminated via peer-reviewed publications and presentations at national and international conferences.

**Authors’ contributions**

EU reviewed/editied the manuscript and is the main study physician in the Graduate School of Medical Science, Kyoto Prefectural University of Medicine. CO is the main study physician in Kyoto First Red Cross Hospital. MF drafted the manuscript and is the principal investigator of the Graduate School of Medical Science, Kyoto Prefectural University of Medicine. All authors designed the study protocol, reviewed and provided edits, and contributed to the discussion and comments on manuscript drafts. EU is the guarantor of this work and, as such, has full access to all the data in the study and will take responsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript.

**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. This trial was conducted with no external funding and was instead funded from operating support funds through the Kyoto Prefectural University of Medicine.

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

This study will be conducted in compliance with the Declaration of Helsinki. Written informed consent will be obtained from each participant after they have been screened for eligibility. Protocol modifications will be approved by the medical research ethics committee of the Hospital of the Kyoto Prefectural University of Medicine, reference number ERB-C-1203. This study has been registered in the University Hospital Medical Information Network clinical trials registry (UMIN000028809).

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamiyogo-ku, Kyoto 602-8566, Japan. 2Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kaji cho, Kamiyogo-ku-Kyoto-city, Kyoto 621-8585, Japan. 3Department of Endocrinology and Metabolism, Kyoto First Red Cross Hospital, 749 Honmachi 15-chome, Higashiyaama-ku, Kyoto 605-0981, Japan. 4Department of Organ Transplantation and General Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamiyogo-ku, Kyoto 602-8566, Japan. 5Department of Biostatistics, Graduate School of Medicine, Hokkaido University, Kita 8, Nishi 5, Kita-ku, Sapporo, Hokkaido 060-0808, Japan.

Received: 17 May 2019 Accepted: 29 October 2019

Published online: 23 December 2019

**References**

1. International Diabetes Federation. Diabetes atlas. 8th ed. Brussels: International Diabetes Federation; 2017. https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/134-idi-diabetes-atlas-8th-edition.html. Accessed 18 Dec 2019.

2. Nanditha A, Ma RC, Ramachandran A, et al. Diabetes in Asia and the Pacific: implications for the global epidemic. Diabetes Care. 2016;39:9472–85.

3. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–49.

4. Ministry of Health, Labour and Welfare: National Health and Nutrition Survey 2016 (Japanese). http://www.mhlw.go.jp/info/health/777189.html. Accessed 5 Apr 2019.

5. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37:1053–9.

6. Hu G, Jousilahti P, Tuomilehto J. Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. Eur Heart J. 2007;28:1059–66.

7. Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ. 1988;297:319–28.

8. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3–10.

9. Ando K, Kawarazaki H, Miura K, et al. [Scientific Statement] Report of the Salt Reduction Committee of the Japanese Society of Hypertension (1) Role of salt in hypertension and cardiovascular diseases. Hypertension Res. 2013;36:1009–19.

10. Presented at the 60th Annual Meeting of the Japan Diabetes Society, Nagoya, Aichi, Japan, May 2016. Available from http://www.jds60.jp/. Accessed 18 Dec 2019.

11. Seino Y, Nanjo K, Tajima N, et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Diabetes Invest. 2010;1:212–28.
12. Shimamoto K, Ando K, Fujita T, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014;37:253–390.

13. Overview of dietary reference intakes for Japanese (2015). Ministry of Health, Labour and Welfare. http://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/Overview.pdf. (Accessed 5 Apr 2019).

14. Bennett JA, Riegel B, Bittner V, et al. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung. 2002;31:262–70.

15. Tanaka T, Okamura T, Miura K, et al. A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen. J Hum Hypertens. 2002;16(2):97–103.

16. Yasuda H, Sanada M, Kitada K, et al. Rationale and usefulness of newly devised abbreviated diagnostic criteria and staging for diabetic polyneuropathy. Diabetes Res Clin Pract. 2007;77(suppl 1):S178-S183.

17. Cramer H, Haller H, Dobos G, et al. A systematic review and meta-analysis estimating the expected dropout rates in randomized controlled trials on yoga interventions. Evid Based Complement Alternat Med. 2016;2016:5859729.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.